ClinConnect ClinConnect Logo
Search / Trial NCT06976632

Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination

Launched by CELAL BAYAR UNIVERSITY · May 14, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Immunization Pain Hemodynamic Parameters Pregnant Women Local Cold Application Helfer Skin Tap Tecnique

ClinConnect Summary

This clinical trial is looking at how a special technique called the Helfer Skin Tap, combined with applying cold to the skin, can help reduce pain during the tetanus vaccine injection in pregnant women. The study not only focuses on how much pain the women feel but also monitors their vital signs, like heart rate and blood pressure, which can change when someone is in pain.

To participate, women must be over 18, pregnant, scheduled for a tetanus vaccine, able to communicate in Turkish, and willing to join the study. They should not have any pain before the injection. However, women who have had certain medical conditions or procedures, or who are experiencing pain, will not be included. If you join the study, you can expect to receive the tetanus vaccine while the researchers apply the cold treatment and monitor your experience. This trial is still recruiting participants, so it’s a good opportunity to contribute to understanding how to make vaccinations more comfortable for pregnant women.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria: Pregnant women who meet the following criteria will be included in the study:
  • Over the age of 18,
  • Scheduled to receive a tetanus vaccine,
  • Able to speak and communicate in Turkish,
  • Willing to participate in the study,
  • Not experiencing any pain for any reason prior to the injection.
  • Exclusion Criteria: Pregnant women who meet any of the following criteria will be excluded from the study:
  • Under the age of 18,
  • Received a tetanus vaccine for reasons other than pregnancy,
  • Received a vaccine other than tetanus,
  • Experiencing pain for any reason prior to the vaccine,
  • Have circulatory disorders or peripheral vascular disease,
  • Have bleeding or clotting disorders,
  • Have a local infection,
  • Used painkillers at least 6 hours prior to the procedure,
  • Underwent a painful procedure within the last hour,
  • Have cold sensitivity,
  • Have cognitive or psychological issues.

About Celal Bayar University

Celal Bayar University is a prominent academic institution dedicated to advancing medical research and clinical practice. With a strong emphasis on innovation and collaboration, the university sponsors clinical trials aimed at exploring new therapeutic approaches and improving patient outcomes. Leveraging its state-of-the-art facilities and a team of experienced researchers, Celal Bayar University fosters an environment that promotes scientific inquiry and ethical standards in clinical research, contributing significantly to the body of medical knowledge and the development of effective healthcare solutions.

Locations

Manisa, , Turkey

Manisa, Uncubozköy/Yunusemre, Turkey

Patients applied

0 patients applied

Trial Officials

Sevgi Pakiş Çetin, Asst. Prof.

Principal Investigator

Celal Bayar University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported